# Rational Design of a Functional Fatty Acid Component for Alleviating Western Diet-Induced Insulin Resistance and Glycolipid Metabolism Disorders

**Authors:** Qingyun Guan, Xia Pi, Feixue Wu, Chunmei Li

PMC · DOI: 10.3390/foods15061016 · 2026-03-13

## TL;DR

This study designed a functional fatty acid blend that reduces insulin resistance and metabolic issues caused by a Western diet in mice and liver cells.

## Contribution

A novel functional fatty acid component (FFAC) was rationally designed and tested to alleviate diet-induced metabolic disorders.

## Key findings

- FFAC reduced weight gain, insulin resistance, and liver fat in mice fed a Western diet.
- FFAC restored insulin signaling and improved gut microbiota composition.
- Unsaturated fatty acids protected liver cells from saturated fatty acid-induced damage.

## Abstract

This research aimed to systematically investigate the regulatory effects of six key fatty acids and rationally designed a functional fatty acid component (FFAC) to alleviate palmitic acid (PA)-induced glycolipid metabolism disorders and insulin resistance (IR) in HepG2 cells and Western diet-induced IR in the C57BL/6 mice model. In vitro experiments showed that saturated fatty acids such as PA and stearic acid (SA) induced concentration-dependent cytotoxicity and IR in HepG2 cells, while unsaturated fatty acids, including palmitoleic acid (POA), oleic acid (OA), linoleic acid (LA), and α-linolenic acid (ALA), enhanced cell viability and exerted protective effects. Based on the principle of balanced fatty acid ratio and the obtained cell experimental results, FFAC was designed as PA:SA:POA:OA:LA:ALA = 4:1:1:4:4:1 and formulated using dietary oils. In vivo, a 13-week dietary intervention revealed that FFAC substitution mitigated Western diet-induced weight gain, systemic IR, serum lipid disorders, and hepatic steatosis in mice. Mechanistically, FFAC restored the IRS1/PI3K/Akt/GSK3β insulin signaling pathway in HepG2 cells and reshaped gut microbiota by enriching beneficial genera such as Akkermansia. These findings demonstrated that FFAC effectively alleviates diet-induced metabolic disorders through multiple pathways, highlighting the potential of rationally designed dietary fatty acid compositions in managing metabolic disorders.

## Linked entities

- **Genes:** IRS1 (insulin receptor substrate 1) [NCBI Gene 3667], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932]
- **Chemicals:** palmitic acid (PubChem CID 985), stearic acid (PubChem CID 5281), palmitoleic acid (PubChem CID 445638), oleic acid (PubChem CID 445639), linoleic acid (PubChem CID 5280450), α-linolenic acid (PubChem CID 5280934)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** Glycolipid Metabolism Disorders (MESH:D008659), weight gain (MESH:D015430), hepatic steatosis (MESH:D005234), lipid disorders (MESH:D011017), IR (MESH:D007333), cytotoxicity (MESH:D064420)
- **Chemicals:** PA (MESH:D019308), POA (MESH:C008757), unsaturated fatty acids (MESH:D005231), OA (MESH:D019301), ALA (MESH:D017962), Fatty Acid (MESH:D005227), LA (MESH:D019787), dietary oils (MESH:D004042), SA (MESH:C031183)
- **Species:** Akkermansia (genus) [taxon 239934], Mus musculus (house mouse, species) [taxon 10090]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025667/full.md

---
Source: https://tomesphere.com/paper/PMC13025667